Release Date: 13-Jan-2022
"Global Cell Therapy Market Outlook, Patent and Clinical Trials Insight 2028" Report Highlights:
The cell therapy is a novel approach of treating damaged or defective cells by replacing them with healthy, functional cells.Since injected live cells have the potential to grow and integrate into the patient to treat diseased tissue, this approach is referred to as regenerative medicine. Several cell therapies have entered the market which is indicated for the management of wide range of diseases including cancer, autoimmune illness, urinary problems, and infectious diseases.
Though CAR T cell therapy is one of the fastest growing segments of the market, but several other areas are also driving the growth across this sector, including the development of stem cell therapies. Stem cells are undifferentiated cells that have the ability to develop into specialized cells under favorable conditions. Furthermore, the stem cells can be harvested from certain tissues or bone marrow of adults or embryos. The stem cell therapy is currently the dominant segment in the market as these therapies gain acceptance as a result of government initiatives. The number of stem cell banks is increasing in developing countries, which is fueling the expansion of the cell treatment industry.
The robust research and development activities by pharmaceutical companies are also favored by government regulatory bodies. The regulatory government are increasingly proving novel drug designations including fast track approval, breakthrough therapy or priority review which accelerate their entry into the market. For instance, Cita-cel (Ciltacabtagene autoleucel) has been granted FDA priority review and is expected to enter the market by 2022. Apart from this, several cell therapy products have been increasingly granted orphan drug designations. The orphan drug designation provides benefits and incentives, including exemption from FDA application fees, assistance in clinical trial design, and seven years of market exclusivity if eventually approved. Recently, two bispecific CAR T cell therapy including GC012F and CT120 have been granted orphan drug designation by US FDA.
The report suggests that the high incidence of cancer and other chronic disorders, increasing investments in pharmaceutical research and development, contract development, and manufacturing organizations (CDM0) investing in advanced technologies, and increasing partnerships and agreements between pharmaceutical companies and CDMO will drive the market growth. Currently, there are more than 1200 ongoing clinical trials which are validating the role of cell therapies in wide range of therapeutic conditions including cancers, Alzheimer, HIV, infections, and others which will drive the growth of market during the forecast period. Other growth factors for the cell therapy market include the establishment of effective guidelines for cell therapy manufacturing, the development of advanced genomic analysis techniques, a large number of research studies by cancer societies, and the proven effectiveness of transplants.
The global cell therapy segment is anticipated to grow with high rates during the forecast period which is mainly driven by the increasing awareness about cell therapy, growing funding for new cell lines, increasing partnerships and acquisitions, and the development of advanced genomics methods for cell analysis. The major key players in the market include Merck, Roche, Oxford Biomedica, Catapult, Novartis, Gracell Biotechnology, among others. The global cell therapy market is expected to almost double during forecast period and is expected to surpass US$ 40 Billion by 2028.
In addition, US, Europe, China, and Japan are the largest cell therapy manufacturing regions which are growing with high CAGR rates, attributed to rising pharmaceutical research and development spending, growing trend for outsourcing drug discovery services, and supportive government. Our report provides comprehensive insights on the commercially available and orphan designated cell therapies and further review of various cell therapy manufacturing initiatives undertaken by big pharmaceutical players engaged in this domain. Further, the report provide insights into cell therapy manufacturing regulations across various geographies, including US, Europe, China, Japan, South Korea, and others.